Inhibitors of Acyl-CoA

In a previous paper, we reported a novel inhibitor of acyl-CoA : cholesterol acyltransferase (ACAT), 2-bromo-N-(2, 6-diisopropylphenyl)-6, 11-dihydrodibenz[b, e]oxepin-11-carboxamide (1). In this work, we prepared both enantiomers and tested them for ability to inhibit ACAT (liver microsomes from ch...

Full description

Saved in:
Bibliographic Details
Published in:Chemical & pharmaceutical bulletin Vol. 44; no. 1; p. 222
Main Authors: KUMAZAWA, Toshiaki, YANASE, Masashi, SHIRAKURA, Shiro, OHISHI, Eiko, YAMADA, Koji, MATSUMIYA, Shigeki, KONO, Motomichi
Format: Journal Article
Language:English
Published: Tokyo Japan Science and Technology Agency 01-01-1996
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a previous paper, we reported a novel inhibitor of acyl-CoA : cholesterol acyltransferase (ACAT), 2-bromo-N-(2, 6-diisopropylphenyl)-6, 11-dihydrodibenz[b, e]oxepin-11-carboxamide (1). In this work, we prepared both enantiomers and tested them for ability to inhibit ACAT (liver microsomes from cholesterol-fed rabbits) in vitro and to decrease serum total cholesterol in cholesterol-fed golden hamsters in vivo. The precursor carboxylic acid 4 was optically resolved with cinchonidine. The obtained (-)- and (+)-4 were converted to (-)- and (+)-1 without racemization, respectively. The enantiomer (-)-1 showed potent ACAT inhibitory activity in vitro with an IC50 value of 8 nM and was approximately 10-fold more active than (+)-1. Furthermore, (-)-1 showed strong hypocholesterolemic activity in vivo, whereas (+)-1 was inactive.A molecular modeling study showed that the difference of ACAT inhibitory activity between the enantiomers was derived from the spatial alignment of the bromine.Compound (-)-1 was selected for further evaluation as KW-3033.
ISSN:0009-2363
1347-5223